Banner Photo
 
Directory of Clinical Studies

ConditionStudyIDTitleStatus
HIV (Adult)AI266-959Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy SubjectsRecruiting
HIV (Adult)AI438-011HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsRecruiting
 AI438-044A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy VolunteersNot yet recruiting
Hepatitis CAI443-131Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)Recruiting
Hepatitis CAI444-257A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis CAvailable
Hepatitis CAI452-016Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical TrialRecruiting
Diabetes (Adult)BCB109Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellitusRecruiting
CancerCA002-001Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid TumorsRecruiting
Cancer, Leukemia (Adult)CA180-330Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world SettingRecruiting
Cancer, Leukemia (Adult)CA180-373A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid LeukemiaRecruiting
Cancer, Leukemia (Adult)CA180-399Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to ImatinibRecruiting
Cancer, Leukemia (Adult)CA180-400This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibRecruiting
Cancer, Leukemia (Adult)CA180-406Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular ResponseRecruiting
Cancer, MelanomaCA184-143A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic MelanomaRecruiting
Cancer, Melanoma (Pediatric), Pediatric StudiesCA184-178Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaRecruiting
Cancer, Solid TumorsCA186-011Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's LymphomaRecruiting
CancerCA186-017Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins LymphomaRecruiting
Colorectal Cancer, Gastrointestinal Cancer, CancerCA186-018Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck CancerRecruiting
CancerCA186-107Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins LymphomaRecruiting
Cancer, Leukemia (Adult)CA204-008Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)Recruiting
Cancer, Leukemia (Adult)CA204-112Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsRecruiting
Lung Cancer, CancerCA209-012Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)Recruiting
Lung Cancer, CancerCA209-026An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)Recruiting
Cancer, Solid TumorsCA209-032A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid TumorsRecruiting
Cancer, MelanomaCA209-038PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaRecruiting
Cancer, Leukemia (Adult)CA209-039Safety Study of Nivolumab and Ipilimumab in Hematologic MalignancyRecruiting
Liver Cancer, CancerCA209-040Dose Escalation Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC) With or Without Chronic Viral HepatitisRecruiting
Lymphoma, Non Hodgkin's Lymphoma, Non Hodgkin's Lymphoma (DLBCL), CancerCA209-139Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)Recruiting
Cancer, Lymphoma, Non Hodgkin's Lymphoma, Non Hodgkin's Lymphoma (Follicular)CA209-140Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)Recruiting
Cancer, Head and Neck cancer (SCCHN)CA209-141Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)Recruiting
Colorectal Cancer, Cancer, Colon Cancer MSI HighCA209-142A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)Recruiting
Glioblastoma, Brain CancerCA209-143A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab Combined With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)Recruiting
Cancer, Lung CancerCA209-153A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)Recruiting
Cancer, MelanomaCA209-168Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody (CheckMate 168)Available
Lymphoma, Hodgkin Lymphoma , CancerCA209-205Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205)Recruiting
Cancer, MelanomaCA209-218Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)Available
Cancer, Solid TumorsCA216-001Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid TumorsRecruiting
Cancer, Leukemia (Adult), Non Hodgkin's Lymphoma, LymphomaCA216-002Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaRecruiting
CancerCA216-003Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid TumorsRecruiting
Cancer, Solid TumorsCA223-001A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid TumorsRecruiting
CancerCA223-002Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorRecruiting
CancerCA224-020Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsRecruiting
CancerCA224-022Safety Study of Anti-LAG-3 in CLL, HL, NHL and MMRecruiting
 CV004-006Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120Recruiting
Diabetes (Pediatric), Pediatric StudiesCV181-058Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 DiabetesRecruiting
Diabetes (Pediatric), Pediatric StudiesCV181-147A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneRecruiting
Diabetes (Adult)CV181-206Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 DiabetesRecruiting
Blood Clots (Pediatric)CV185-118Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic DisorderRecruiting
Diabetes (Adult), Kidney DiseaseCV202-010Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney DiseaseRecruiting
 CV205-005A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial FibrillationRecruiting
Rheumatoid ArthritisIM001-001A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male SubjectsRecruiting
 IM006-001Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy SubjectsRecruiting
Rheumatoid ArthritisIM101-121Abatacept Pregnancy Exposure RegistryRecruiting
Rheumatoid ArthritisIM101-240An Observational Registry of Abatacept in Patients With Juvenile Idiopathic ArthritisRecruiting
Lupus, Lupus NephritisIM101-291Efficacy and Safety Study of Abatacept to Treat Lupus NephritisRecruiting
Rheumatoid Arthritis, Pediatric StudiesIM101-301Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)Recruiting
TransplantationIM103-076Evaluating Nulojix (Belatacept) Long-Term Safety in TransplantRecruiting
TransplantationIM103-116A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-BasedRecruiting
Renal Transplant (Pediatric), Pediatric StudiesIM103-144Phase II Pharmacokinetics, Efficacy, and Safety of Belatacept in Pediatric Renal Transplant RecipientsRecruiting
Rheumatoid ArthritisIM133-066Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid ArthritisRecruiting
Idiopathic Pulmonary Fibrosis, Lung DiseaseIM136-003Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisRecruiting
 IM136-106To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy VolunteersRecruiting
 IM142-003Study to Evaluate the Safety, Tolerability, PK, and PD of CD40 in Healthy SubjectsRecruiting
Diabetes (Pediatric), Pediatric StudiesMB102-091PK Study of Dapagliflozin in Pediatric Subjects With T2DMRecruiting
Diabetes (Adult)MB130-002A Study to Evaluate BMS-986036 in Obese Adults With Type-2 DiabetesRecruiting